Annovis: Alzheimer’s Phase 2/3 Topline Readout Puts Buntanetap Future Into Question (ANVS)
J Studios Thesis I have covered Annovis Bio (NYSE:ANVS) before with a Hold rating in October 2023. At the time, Annovis had not yet released any topline readout from their Phase 3 trial in Parkinson’s and their Phase 2/3 trial in Alzheimer’s. The Phase 2/3 results in Alzheimer’s have just been released. The press release,…